Tiziana Life Sciences PLC AIM Delisting and Admission to the Main Market
January 20 2021 - 2:00AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
20 January 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
AIM Delisting and Admission to the Standard Listing Segment of
Main Market
New York/London, 20 January 2021 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation, and infectious diseases, today provided a
further update with respect to the cancellation of admission of its
Ordinary Shares to trading on AIM and admission to listing of its
ordinary shares (the "Ordinary Shares") on the standard listing
segment of the Official List of the Financial Conduct Authority
("FCA") (the "Official List") and admission to trading on the main
market for listed securities (the "Main Market") of London Stock
Exchange plc (the "London Stock Exchange") (together,
"Admission").
As previously announced, the last day of trading of the
Company's Ordinary Shares on AIM will be today, 20 January 2021 and
the AIM Delisting will be effective from 7.00 am 21 January 2021.
Admission of shares to the Official List and commencement of
dealing in the Ordinary Shares of the Company on the Main Market
will be effective from 8.00 am on 21 January 2021.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &
UK AIMS: TILS) biotechnology company that focuses on the discovery
and development of novel molecules to treat human diseases in
oncology, inflammation and infectious diseases. In addition to
milciclib, the Company will be shortly initiating Phase 2 studies
with orally administered Foralumab for Crohn's Disease and nasally
administered Foralumab for progressive multiple sclerosis.
Foralumab is the only fully human anti-CD3 monoclonal antibody
(mAb) in clinical development in the world. This Phase 2 compound
has potential application in a wide range of autoimmune and
inflammatory diseases, such as Crohn's Disease, multiple sclerosis,
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is
desirable. The company is accelerating development of
anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
For further enquiries:
United Kingdom:Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDBGSBDGBC
(END) Dow Jones Newswires
January 20, 2021 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Oct 2023 to Oct 2024